D&D Pharmatech publishes 12-week Phase 2 zabopegdutide MASH data

Lancet Gastroenterology & Hepatology paper showed early liver fat, stiffness and fibrosis biomarker gains that preceded positive 48-week biopsy outcomes, while benefits also appeared in patients with limited early weight loss.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.